Acute Ischemic Stroke Following Cardioversion in a Patient Receiving Dabigatran

Annals of Pharmacotherapy

Volumn 47, Issue 10, 2013, Pages 1368-1371

  Faust, Andrew C ^a   Smith, Megan B ^a,b   Kawalsky, Darryl ^c  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c North Texas Poison Center   (United States)

Author keywords

cardioversion; dabigatran; ischemic stroke

Indexed keywords

AMIODARONE; DABIGATRAN; LANSOPRAZOLE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CARDIOVERSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMIPARESIS; HEMIPLEGIA; HUMAN; INFLAMMATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSITIONAL BLINDNESS; TREATMENT DURATION;

CARDIOVERSION; DABIGATRAN; ISCHEMIC STROKE;

AGED; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; ELECTRIC COUNTERSHOCK; HUMANS; MALE; STROKE;

EID: 84888028352     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013500941     Document Type: Article

References (20)

1. Cardiovascular and Renal Drugs Advisory Committee. September20, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM236322.pdf. Accessed July 27, 2013.
2. Connolly SJ,Ezekowitz MD,Yusuf Set al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009;361:1139-1151.
3. Nagarakanti R,Ezekowitz MD,Oldgren Jet al.Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.Circulation. 2011;123:131-136.
4. You JJ,Singer DE,Howard PA, et alChest. 9th ed. Chest. 2012;141:e531S-e575S.2012:e531S-e575S.
5. Fuster V,Ryden LE,Cannom DSet al.ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report from the American College of Cardiology/American Heart Association task force on practice guidelines and European Society of Cardiology Committee for practice guidelines.J Am Coll Cardiol. 2006;48:e149-e246.
6. Bjerkelund CJ,Orning OM.The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation.Am J Cardiol. 1969;23:208-216.
7. Klein AL,Grimm RA,Murray RDet al.Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.N Engl J Med. 2001;344:1411-1420.
8. Black IW,Fatkin D,Sagar KBet al.Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study.Circulation. 1994;89:2509-2513.
9. Johnson & Johnson Pharmaceutical Research and Development, LLC;.
10. Flaker G,Lopes R,Al-Khatib Set al.Abstract 4048: Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE trial.Eur Heart J. 2012;33:686.
11. Buch TN,Holm J,Munck LK.Extensive thromboembolism after cardioversion in a patient treated with dabigatran [in Danish].Ugeskr Laeger. 2013;175:333-334.
12. Van Ryn J,Stangier J,Haertter et al.Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.Thromb Haemost. 2010;103:1116-1127.
13. Stangler J,Stahle H,Rathgen Ket al.Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subject.Clin Pharmacokinet. 2008;47:47-59.
14. Liesenfeld KH,Lehr T,Dansirikul Cet al.Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.J Thromb Haemost. 2011;9:2168-2175.
15. Davis EM,Packard KA,Knezevich JTet al.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Pharmacotherapy. 2011;31:975-1016.
16. Khan IA.Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.Am Heart J. 2002;144:11-22.
17. Fatkin D,Kelly RP,Feneley MP.Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo.J Am Coll Cardiol. 1994;23:961-969.
18. Uchino K,Hernandez AV.Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.Arch Intern Med. 2012;172:397-402.
19. Christersson C,Oldgren J,Wallentin Let al.Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.J Intern Med. 2011;270:215-223.
20. Ezekowitz MD,Reilly PA,Nehmiz Get al.Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study).Am J Cardiol. 2007;100:1419-1426.